reason report
rx separ take time consum strategi earli
bottom line time rx separ nebul
given manag comment call investor view
expos uncertainti surround gener sector
explain stock reaction post earn today despit
believ reason quarter transform consum
busi manag made earli progress oper servic
level sale realign bigger transform faster
grow busi take time addit trial date irish tax
case april could present overhang stock head
event
re-evalu time rx separ given industri dynam
probabl right decis add near term uncertainti
rx busi clear posit differenti vs us gener peer
better product mix price fix opioid liabil exposur hard
imagin separ discuss last month
posit impact given valuat us gener peer
fallen result headlin manag remain
commit separ busi right valu
like need quarter oper stabil along
key product approv gx proair addit stabil
manag remain commit deliv organ
growth csca remain track deliv manag
reiter expect get organ growth csca
augment bolt-on acquisit time ranir
acquisit complet manag continu see busi
high-single/low-doubl digit grower track deliv
organ growth rang new product launch
sale met consensu expect despit disrupt infant formula
manag believ back track year end infant
formula manufactur issu drag mani month
product recal also headwind howev manag
believ consum demand close pre-recal level expect
busi along nutrit stabil appear
exit brand infant formula mean manag need
reassess longer term goal core busi store brand
still seem well
ev/ebitda multipl incl
net debt total capit
year price history/av daili volume mil
compani inform svb leerink llc research
revenu
pleas refer page import disclosur price chart analyst certif
sale forc realign csci expect complet
sale impact sale forc align
impact felt particularli franc hit top-
line overal manag like need remaind year
hire train deploy new salespeopl howev new product
sale particular weight loss derm drove strong sale
quarter manag see continu reiter
csci transform well underway
develop irish revenu tax assess would
come april new news manag note
date late april set judici review recal
judici review issu rule merit case
instead decid whether irish revenu bring forth assess
manag previous indic believ likelihood win
judici review low ultim serv forum perrigo
get posit argument may use tax appeal
chang model lower revenu entir
rx gross margin rx segment well-
expect see increas closer
rang make minim chang csca csci
increas csca revenu new launch revenu
come higher expect overal lower
ep ebitda minim
chang vs appli multipl yield
rate market perform believ consum self-car america csca like
continu grow low-singl digit consum self-car csci also grow
low-singl digit growth potenti manag initi take time play
view howev unclear decis separ rx busi
immedi unlock valu enhanc growth consum healthcar segment
current still limit visibl medium-/long-term growth trajectori
busi final see signific uncertainti around tysabri royalti tax liabil rule
ireland us whether may abl win appeal long take
get appeal decis
use ebitda appli weight averag ev/ebitda multipl
account potenti tax liabil arriv pt
limit rx-to-otc switch opportun and/or delay new rx over-the-counter product launch
could result share trade lower expect initi drive busi may
success anticip lead share perform better expect uncertainti
time and/or natur separ gener busi uncertainti time
eventu liabil amount relat tysabri ip sale
csca net sale guidanc may includ ranir august guidanc incorpor ranir contribut
consum self-car americasnet oper marginconsum self-car internationalnet oper marginrx pharmaceuticalsnet oper margintot adjust net dsg oper effect tax share outstandingoper compani plc
figur chang model
svb leerink estim note number except ep margin
figur chang model continu
svb leerink estim note number except ep margin
note revenu
changevalu changevarianceconsensusactu vs conssegmentscsc dilut non-gaap adjustmentstot one-tim net perrigo compani plc
note revenu
brand
type event
event trial detail
date known
up/down
expect
svb leerink llc equiti research compani file
number except per share data
net debt ebitda ratio
number except per share data
number except per share data
growth excl ah food bizexit
long term growth
number except per share data
gsk product yokeb
number except per share data
gx finacea foam azela acid progress month stay expir juli
gx soolantra cream ivermectin rosacea ftf case progress
number except per share data
tysabri royalti stream fair valu
payrol relat tax
number except per share data
adjust reconcil ni net cash oper
tysabri toyalti stream chang fair valu
loss extinguish debt
impair equiti invest net
decreas increas work capit
proce royalti right
acquisit businesses/asset net cash acquir
proceed sale busi
settlement acquisition-rel foreign currenc deriv
purchas properti plant equip capital-expenditure
net invest
borrow repay revolv credit/oth net
premium earli debt retir
issuanc ordinari share
net financ
effect exchang rate chang cash/ cash equival
net chang equival
